Medivir AB (publ) (OTCMKTS:MVRBF – Get Rating) is one of 404 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Medivir AB (publ) to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, profitability, institutional ownership and risk.
Profitability
This table compares Medivir AB (publ) and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medivir AB (publ) | N/A | N/A | N/A |
| Medivir AB (publ) Competitors | -483.89% | -67.84% | -25.01% |
Valuation & Earnings
This table compares Medivir AB (publ) and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Medivir AB (publ) | N/A | N/A | 0.03 |
| Medivir AB (publ) Competitors | $375.79 million | $54.07 million | 19.12 |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Medivir AB (publ) and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medivir AB (publ) | 0 | 0 | 1 | 0 | 3.00 |
| Medivir AB (publ) Competitors | 829 | 1966 | 6183 | 80 | 2.61 |
Medivir AB (publ) currently has a consensus target price of $50.00, indicating a potential upside of 5,997.56%. As a group, “Biotechnology” companies have a potential upside of 124.05%. Given Medivir AB (publ)’s stronger consensus rating and higher probable upside, analysts plainly believe Medivir AB (publ) is more favorable than its peers.
Institutional and Insider Ownership
23.2% of Medivir AB (publ) shares are owned by institutional investors. Comparatively, 28.0% of shares of all “Biotechnology” companies are owned by institutional investors. 23.9% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Medivir AB (publ) beats its peers on 6 of the 11 factors compared.
About Medivir AB (publ)
-logo.png){kind=logo}
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
